Cite
HARVARD Citation
Kallen, K. et al. (n.d.). A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses. Journal for immunotherapy of cancer. p. . [Online].